Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum

  • Authors:
    • Hector R. Galván‑Salazar
    • Alejandro D. Soriano‑Hernández
    • Daniel A. Montes‑Galindo
    • Gabriel Ceja Espíritu
    • José Guzman‑Esquivel
    • Iram P. Rodríguez‑Sánchez
    • Oscar A. Newton‑Sánchez
    • Margarita L. Martinez‑Fierro
    • Xóchitl G. Briseño Gómez
    • Augusto Rojas‑Martínez
    • Iván Delgado‑Enciso
  • View Affiliations

  • Published online on: September 8, 2016     https://doi.org/10.3892/mco.2016.1013
  • Pages: 657-659
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Adenocarcinoma of the duodenum comprises 50‑70% of duodenal tumors. There is an increase in extracellular matrix metalloproteinases in this disease and it has been suggested that they play an important role in the development and pathology. Therefore, new therapeutic recommendations based on inhibitors of these enzymes, such as doxycycline, are under investigation. The cytotoxic effect of doxycycline was evaluated in the HuTu‑80 duodenal adenocarcinoma cell line and its antitumor effect was determined in an immunodeficient murine model. A 10‑µM (4.4 µg̸ml) concentration of doxycycline was capable of causing apoptosis in 90% of the culture cells. doxycycline was also responsible for a decrease in tumor growth and an increase in the survival of the mice with HuTu‑80‑cell tumors. These results suggest that doxycycline is a potential cytotoxic and antitumor agent effective in the treatment of adenocarcinoma of the duodenum.
View Figures
View References

Related Articles

Journal Cover

November 2016
Volume 5 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Galván‑Salazar, H.R., Soriano‑Hernández, A.D., Montes‑Galindo, D.A., Ceja Espíritu, G., Guzman‑Esquivel, J., Rodríguez‑Sánchez, I.P. ... Delgado‑Enciso, I. (2016). Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum. Molecular and Clinical Oncology, 5, 657-659. https://doi.org/10.3892/mco.2016.1013
MLA
Galván‑Salazar, H. R., Soriano‑Hernández, A. D., Montes‑Galindo, D. A., Ceja Espíritu, G., Guzman‑Esquivel, J., Rodríguez‑Sánchez, I. P., Newton‑Sánchez, O. A., Martinez‑Fierro, M. L., Briseño Gómez, X. G., Rojas‑Martínez, A., Delgado‑Enciso, I."Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum". Molecular and Clinical Oncology 5.5 (2016): 657-659.
Chicago
Galván‑Salazar, H. R., Soriano‑Hernández, A. D., Montes‑Galindo, D. A., Ceja Espíritu, G., Guzman‑Esquivel, J., Rodríguez‑Sánchez, I. P., Newton‑Sánchez, O. A., Martinez‑Fierro, M. L., Briseño Gómez, X. G., Rojas‑Martínez, A., Delgado‑Enciso, I."Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum". Molecular and Clinical Oncology 5, no. 5 (2016): 657-659. https://doi.org/10.3892/mco.2016.1013